AAM
PTGX icon

Advisors Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Advisors Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,644
Closed -$489K – 1477
2026
Q1 		$489K Sell
4,644
-60
-1% -$5.31K 0.01% 971
2025
Q4 		$411K Sell
4,704
-2
-0% -$164 0.01% 1004
2025
Q3 		$313K Sell
4,706
-18
-0.4% -$1.02K 0.01% 1052
2025
Q2 		$261K Buy
4,724
+3
+0.1% +$144 ﹤0.01% 1071
2025
Q1 		$228K Buy
4,721
+2,123
+82% +$89K ﹤0.01% 1084
2024
Q4 		$100K Buy
+2,598
New +$113K ﹤0.01% 1223

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Advisors Asset Management's PTGX Position: Q2 2026 in Review

Advisors Asset Management sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 4,644 shares — an estimated $489K sold.

Advisors Asset Management first reported a position in PTGX in Q4 2024 and held it in 6 quarters. The position peaked at $489K in Q1 2026. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Advisors Asset Management reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Advisors Asset Management sold 4,644 Protagonist Therapeutics shares in Q2 2026, an estimated $489K.
  • Advisors Asset Management first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 6 quarters.
  • Advisors Asset Management's Protagonist Therapeutics position peaked at $489K in Q1 2026.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.